Classes
Publications
- Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells2013 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity2020 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from theCardio-Oncology Study Groupof theHeart Failure Associationand theCardio-Oncology Council of the European Society of Cardiology2020 | Faculty of Medicine in Hradec Králové
- In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline2019 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
Loading network view...